Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telix Pharmaceuticals ( (AU:TLX) ) just unveiled an update.
Telix Pharmaceuticals has scheduled its 2026 Annual General Meeting for May 21 in Melbourne, offering both in-person attendance at The Events Centre on Collins Street and online participation via a dedicated webcast platform. The company has distributed a shareholder pack, including the formal notice, proxy form and online guide, underscoring its focus on accessibility and engagement for its global investor base.
The AGM announcement signals a routine yet important governance milestone for Telix as it continues to expand its radiopharmaceutical portfolio in oncology and rare diseases across multiple international markets. By facilitating hybrid attendance, Telix is catering to its geographically dispersed shareholders, which may support broader participation in corporate oversight and strengthen investor relations as the company pursues its growth strategy.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals aimed at addressing significant unmet medical needs in oncology and rare diseases. Headquartered in Melbourne, it operates across the United States, United Kingdom, Brazil, Canada, several European markets and Japan, and is dual-listed on the ASX and Nasdaq.
YTD Price Performance: 32.14%
Average Trading Volume: 3,408,551
Technical Sentiment Signal: Buy
Current Market Cap: A$5.02B
See more data about TLX stock on TipRanks’ Stock Analysis page.